Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 11,312
- Institution
- University of Washington
External Links
Identifiers
- ORCID
- 0000-0002-3232-4515
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.